Addex Therapeutics to Release Half-Year 2020 Financial Results and Host Conference Call on August 12, 2020
August 10 2020 - 1:00AM
Geneva, Switzerland, August 10,
2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a
leading company pioneering allosteric modulation-based drug
discovery and development, will discuss its half-year 2020
financial results, provide a business update and review its
pipeline during a teleconference and webcast for investors,
analysts and the media on Wednesday, August 12 at 16:00 CEST (14:00
GMT/10:00 ET).
Title:
Addex Half-Year 2020 Financial Results Conference
CallDate:
August 12,
2020Time:
16:00 CEST (14:00 GMT/10:00 ET)
Joining the Conference
Call:
In the 10 minutes prior to the call start time,
call the appropriate participant dial-in number.
Dial-in numbers:
Switzerland: +41 44
58 06 522United States: +1 877
4230830United Kingdom: +44 203 0092470
Link for other countries
Participation Pin Code: 22285484#
Connect to live event: Link
Password: Welcome
About Addex Therapeutics:Addex
Therapeutics is a clinical-stage pharmaceutical company
focused on the development and commercialization of an emerging
class of novel orally available small molecule drugs known as
allosteric modulators for neurological disorders. Allosteric
modulators offer several potential advantages over conventional
non-allosteric molecules and may offer an improved therapeutic
approach to conventional "orthosteric" small molecule or biological
drugs. Addex's allosteric modulator drug discovery platform targets
receptors and other proteins that are recognized as essential for
therapeutic intervention. Addex's lead drug candidate, dipraglurant
(mGlu5 negative allosteric modulator or NAM), is scheduled to enter
a pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's
therapeutic use in dystonia is being investigated in preclinical
models. Addex's second clinical program ADX71149 (mGlu2 positive
allosteric modulator or PAM), developed in collaboration with
Janssen Pharmaceuticals, Inc., is scheduled to enter a Phase 2a
proof of concept clinical study for the treatment of epilepsy. In
addition, Addex’s GABAB PAM program has been licensed to
Indivior PLC for the treatment of addiction. Preclinical programs
include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for
mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease
and mGlu3 PAM for neurodegenerative
disorders.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55Email:
PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Forward Looking
Statements:Certain statements made in this announcement
are forward-looking statements including with respect to the
creation of a trading market for ADSs representing the Company's
shares in the United States. These forward-looking statements
are not historical facts but rather are based on the Company's
current expectations, estimates, and projections about its
industry; its beliefs; and assumptions. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements. The Company cautions
securityholders and prospective securityholders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Sep 2023 to Sep 2024